Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00751218
Other study ID # P03735
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 6, 2004
Est. completion date May 24, 2005

Study information

Verified date February 2022
Source Organon and Co
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.


Recruitment information / eligibility

Status Completed
Enrollment 174
Est. completion date May 24, 2005
Est. primary completion date May 24, 2005
Accepts healthy volunteers No
Gender All
Age group 12 Years to 70 Years
Eligibility Inclusion Criteria: - Have demonstrated their willingness to participate in the study and comply with its procedures by signing a written informed consent. For pediatric patients, the parent or legal guardian was to have signed a written informed consent. - Be between 12 and 70 years of age, of either sex and any race. - Had signs and symptoms of CIU for at least 6 weeks prior to the Screening Visit. - Have been experiencing a current flare of their CIU of at least 3 weeks prior to the Baseline Visit. Hives were to have been present for at least 3 days per week during the current flare prior to the Baseline Visit. - Have an overall condition of CIU that was at least of "moderate" severity (minimum score of 2) at both Screening and Baseline Visits. - Have at least a moderately severe pruritus score (minimum score of 2) and hives (minimum score of 1) present at Screening. - Have, at Baseline, a total pruritus score of >= 14 for the sum of AM and PM (reflective) diary scores for the 3 days prior to Baseline and the AM diary score on Day 1. - Understand and be able to adhere to the dosing and visit schedules, and agree to assess and record their symptom severity scores, medication times, concomitant medications, and adverse events accurately and consistently in a daily diary. - Be in general good health and free of any clinically significant disease (other than CIU) that would have interfered with study evaluations. - If female and of childbearing potential, have had a negative urine (hCG) pregnancy test at the time of Baseline (Visit 2). - Female subjects of childbearing potential were to be counseled in the appropriate use of birth control while in the study. They were to be using a medically accepted method of birth control Exclusion Criteria: - Had asthma requiring chronic use of inhaled or systemic corticosteroids. - Had been unresponsive to antihistamine treatment in the past. - Had a history of allergies to more than two classes of medication or who were allergic to or unable to tolerate antihistamines. - Had used any investigational drug in the last 30 days prior to Baseline. - Had food or drug allergies manifested as skin reactions. Subjects with urticaria that was primarily due to physical urticaria or other known etiology. - If female, were pregnant or nursing. - Had a history of hypersensitivity to the study drug or its excipients. - Were family members of the investigational study staff involved with this study. - Had previously been randomized into the study. - Had current evidence of clinically significant hematopoietic, cardiovascular, hepatic, renal, neurologic, psychiatric, autoimmune disease, or other disease that precluded the subject's participation in the study. Particular attention was to be given to subjects with conditions that would interfere with the absorption, distribution, metabolism, or excretion of the study medication or with the subject's ability to reliably complete the diary card. - Were morbidly obese (BMI >= 35, as described in Appendix 6 of the protocol) - Had a compromised ability to provide informed consent. - Had a history of non-compliance with medications or treatment protocols.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
desloratadine
desloratadine, 5mg oral tablets, once daily for 28 days
placebo
placebo, once daily for 28 days
cetirizine
cetirizine, 10 mg capsules once daily for 28 days

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Organon and Co

Outcome

Type Measure Description Time frame Safety issue
Primary Compare the efficacy of the study treatments with respect to the change from Baseline in the average AM/PM 12-hour reflective pruritus severity score (diary recordings) after the first 7 days of treatment. 7 days
Secondary Joint physician-patient evaluations ("now") at treatment days 14 and 28 (Visit 3 and 4) of overall condition of the CIU and overall global therapeutic response Days 14 and 28 (visits 3 and 4)
Secondary Average AM/PM "reflective" diary scores over for: severity of pruritus; number of hives; size of largest hives; total symptom score; subject-evaluated CIU interference with sleep (AM) and interference with daily activities (PM). Treatment days 1-7, 8-14, 15-21 and 22-28
Secondary Adverse event reports and vital sign evaluations Upon occurance
See also
  Status Clinical Trial Phase
Terminated NCT03693625 - A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study Phase 2
Recruiting NCT03545464 - COrticosteroids in acUte uRticAria in emerGency dEpartment Phase 3
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Not yet recruiting NCT00163839 - The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema N/A
Terminated NCT00069329 - Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease N/A
Completed NCT00876369 - Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
Terminated NCT00199238 - Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria Phase 2
Completed NCT02576041 - Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Phase 4
Completed NCT00724698 - Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Completed NCT02238249 - Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria N/A
Completed NCT00001150 - Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers N/A
Completed NCT03296358 - Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department. N/A
Completed NCT00130234 - Effect of Anti-IgE in Chronic Urticaria Phase 2
Completed NCT00795158 - How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988) Phase 3
Completed NCT00368823 - A Trial of Point of Care Information in Ambulatory Pediatrics Phase 3
Completed NCT02424799 - Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 Phase 1
Completed NCT01371877 - The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment N/A
Completed NCT03137069 - A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU). Phase 2
Recruiting NCT05115136 - Using Doxepin for Urticaria Phase 3
Terminated NCT02382562 - Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients N/A